Varian Acquires CyberHeart

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

May 9, 2019: Varian today announced it has acquired CyberHeart, a privately-held company with intellectual property (IP) that covers the use of radiation in the heart (cardiac radioablation) and other forms of radiosurgery for cardiovascular disease.

“Based on the early positive clinical results in ventricular tachycardia we have seen from other investigators, we believe that this technology can offer hope to cardiac arrhythmia patients,” said Dee Khuntia, chief medical officer at Varian. “Cardiac radioablation would truly be a paradigm shift, bringing together two specialties—radiation oncology and cardiac electrophysiology—to collaborate in the treatment of cardiac patients.”

“Varian has a long track record of innovations in the field of radiation medicine and has successfully commercialized radiosurgery technology for treating both benign and malignant lesions,” said Kolleen Kennedy, president of Varian Proton Solutions & chief growth officer.  “We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space.”

First in-human studies of radioablation in the treatment of cardiac arrhythmias have been published in the New England Journal of Medicine1 and Circulation2.

“While cardiac radioablation technologies are not yet approved by the FDA, we feel that the results of these recent early studies are promising enough to warrant investment in this area,” Kennedy said.  “We’re now working to evaluate the CyberHeart IP portfolio and determine priorities for development and clinical trials going forward.”

Varian’s acquisition of CyberHeart involved the transfer of IP.


References

1 Cuculich, Phillip S., et al. “Noninvasive cardiac radiation for ablation of ventricular tachycardia.” New England Journal of Medicine 377.24 (2017): 2325-2336.

2 Robinson, Clifford G., et al. “Phase I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia.” Circulation 139.3 (2019): 313-321.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.